Teva Pharmaceuticals USA, Inc., a leading global pharmaceutical company, announced that the company has settled the patent litigation with AstraZeneca Pharmaceuticals LP, AstraZeneca AB and Amylin Pharmaceuticals, LLC (AstraZeneca) relating to AstraZeneca’s US Patent Nos. 6,858,576, 6,872,700, 6,956,026, 7,297,761, 6,902,744, 7,521,423, and 7,741,269 and AstraZeneca’s Byetta (exenatide), and entered into a settlement and license agreement with AstraZeneca, pursuant to which AstraZeneca granted a license to Teva to manufacture and commercialize the generic version of Byetta described in Teva’s ANDA No. 205984 in the United States.

The settlement allows Teva to commercialize its generic version of Byetta (exenatide injection) in the US beginning October 15, 2017 or earlier under certain circumstances. All other terms of the agreement are confidential.

Byetta (exenatide injection) is an injectable product used to treat type 2 diabetes.

Teva remains committed to strengthening its presence in its generic injectable business globally. Teva continues investment in new, and higher-value generic injectable products. With approximately 370 generic medicines available, Teva has the largest portfolio of FDA-approved generic products and continues to bring new products to market for the patients who need them.